Triple-Negative Breast Cancer Clinical Trials

205 recruitingLast updated: June 6, 2026

There are 205 actively recruiting triple-negative breast cancer clinical trials across 43 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Triple-Negative Breast Cancer Trials at a Glance

205 actively recruiting trials for triple-negative breast cancer are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 100 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running triple-negative breast cancer studies include Fudan University, H. Lee Moffitt Cancer Center and Research Institute, and Memorial Sloan Kettering Cancer Center.

Browse triple-negative breast cancer trials by phase

Treatments under study

About Triple-Negative Breast Cancer Clinical Trials

Looking for clinical trials for Triple-Negative Breast Cancer? There are currently 156 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Triple-Negative Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Triple-Negative Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 205 trials

Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Early Phase 1

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Triple-Negative Breast Cancer
University of Alabama at Birmingham20 enrolled1 locationNCT04861077
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 2

Sacituzumab Govitecan In TNBC

Triple-Negative Breast CancerHER2-negative Breast CancerInvasive Breast Cancer+2 more
Massachusetts General Hospital260 enrolled5 locationsNCT04230109
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled297 locationsNCT06393374
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1Phase 2

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Triple-Negative Breast Cancer
NEC Bio B.V28 enrolled2 locationsNCT06631092
Recruiting
Phase 2

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
Jiangsu Cancer Institute & Hospital34 enrolled1 locationNCT07601178
Recruiting
Phase 1Phase 2

Saci Nivo Rela for TNBC

Metastatic Triple-negative Breast Cancer
Yale University60 enrolled1 locationNCT06963905
Recruiting
Phase 2

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Triple-Negative Breast Cancer
Queen Mary University of London140 enrolled2 locationsNCT06954480
Recruiting
Phase 2

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center700 enrolled2 locationsNCT07340541
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled33 locationsNCT06465069
Recruiting
Phase 1Phase 2

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Metastatic Triple-negative Breast Cancer
M.D. Anderson Cancer Center31 enrolled1 locationNCT07011654
Recruiting
Phase 1

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT06246968
Recruiting
Phase 1

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple-Negative Breast Cancer
University of Southern California20 enrolled1 locationNCT05989828
Recruiting
Phase 2

Study of Screening Brain MRIs in Stage IV Breast Cancer

Triple-Negative Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute170 enrolled2 locationsNCT05115474
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled45 locationsNCT05005403
Recruiting
Early Phase 1

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

TNBC - Triple-Negative Breast CancerLocally Advanced Triple Negative Breast Cancer
Rima Patel15 enrolled1 locationNCT06637306
Recruiting
Phase 1

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Triple-Negative Breast CancerColorectal, CancerSarcoma+5 more
Valo Therapeutics Oy15 enrolled7 locationsNCT05492682